Core Viewpoint - The company has received approval from the National Medical Products Administration (NMPA) for clinical trials of its innovative drug BIOS-0623-Z4, which targets adult cancer pain relief and is the first of its kind in its mechanism and indication [1] Group 1: Drug Development - BIOS-0623-Z4 is a non-opioid drug developed by the company, specifically designed for the treatment of adult cancer pain [1] - The drug is classified as a Class 1 medication and has no other drugs on the market with the same target mechanism and indication [1] - The clinical trial application for BIOS-0623-Z4 was accepted on July 10, 2025, and has been approved for clinical trials to relieve adult cancer pain [1] Group 2: Regulatory Approval - The approval was granted based on the review of the application in accordance with the Drug Administration Law of the People's Republic of China and relevant regulations [1] - The approval indicates that the clinical trial application meets the necessary requirements for drug registration [1]
百诚医药：创新药BIOS-0623-Z4片获得临床试验批准通知书